SUS Single Use System for Biopharma Process Market Size, Share, Growth, and Industry Analysis, By Type (Single-use Bioreactor, Disposable Sterile Bags, Disposable Filtration System, Other), By Application (Bio-pharmacy, CDMO), Regional Insights and Forecast to 2035

SUS Single Use System for Biopharma Process Market Overview

The global SUS Single Use System for Biopharma Process Market size estimated at USD 9924.34 million in 2026 and is projected to reach USD 70458.23 million by 2035, growing at a CAGR of 24.33% from 2026 to 2035.

The SUS Single Use System for Biopharma Process Market is expanding rapidly due to increasing adoption of disposable technologies in biologics manufacturing, vaccines, and cell and gene therapy production. Over 70% of biopharmaceutical facilities now integrate single-use technologies to enhance flexibility and reduce contamination risks. More than 65% of upstream processing units utilize SUS components such as bioreactors and filtration assemblies. The market is driven by the rise in biologics production volumes exceeding 400 million liters annually and growing demand for cost-efficient manufacturing solutions. SUS Single Use System for Biopharma Process Market Analysis highlights significant adoption in monoclonal antibody production, accounting for over 60% of total biologics output globally.

In the USA, SUS Single Use System for Biopharma Process Market Insights reveal that over 75% of biopharma companies have implemented single-use systems across manufacturing pipelines. Approximately 68% of contract manufacturing organizations rely on SUS for rapid scale-up and flexible production. More than 500 biologics manufacturing facilities in the USA utilize disposable bioprocessing technologies. The demand is further driven by over 1,200 ongoing biologics and biosimilar development programs. SUS adoption in upstream processing exceeds 70%, while downstream processing integration has crossed 55%. SUS Single Use System for Biopharma Process Market Trends indicate increased investment in modular bioprocessing facilities across major pharmaceutical hubs in the USA.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: The market is driven by a 68% increase in biologics production demand, alongside a 72% rise in vaccine manufacturing capacity, with 65% adoption of disposable systems for contamination control and 70% preference for flexible manufacturing setups.
• Major Market Restraint: The market faces challenges due to 55% concerns over extractables and leachables, 48% limitations in scalability, 52% dependency on plastic materials, and 46% supply chain disruptions impacting availability.
• Emerging Trends: The market is evolving with a 62% shift toward modular facilities, 58% integration of automation in SUS, 64% growth in cell and gene therapy applications, and 60% adoption of hybrid bioprocessing systems.
• Regional Leadership: North America leads with 38% market share, followed by Europe at 30%, Asia-Pacific at 25%, and the rest of the world holding 7% with steadily increasing adoption rates.
• Competitive Landscape: The competitive environment shows 45% dominance by top 5 players, 35% contribution from mid-tier companies expanding portfolios, and 20% presence of new entrants focusing on innovation and customization.
• Market Segmentation: The market is segmented into 60% upstream processes, 30% downstream processes, and 10% fill-finish applications, with increasing adoption across all segments.
• Recent Development: Recent developments include 66% investment in R&D for advanced SUS materials, 59% expansion of manufacturing capacities, 63% increase in partnerships and collaborations, and 61% innovation in filtration technologies.

SUS Single Use System for Biopharma Process Market Latest Trends

The SUS Single Use System for Biopharma Process Market Trends are increasingly shaped by the growing adoption of continuous bioprocessing and modular facility designs. Over 60% of new biopharmaceutical plants are designed with single-use technologies to enable rapid deployment and scalability. The demand for disposable bioreactors has exceeded 65% usage in upstream processing due to their efficiency and reduced cleaning requirements. SUS Single Use System for Biopharma Process Market Growth is further supported by the expansion of cell and gene therapies, with over 1,000 clinical trials globally utilizing single-use components in production processes. Automation integration in SUS has increased by 58%, improving process consistency and reducing human intervention.

Another significant trend in the SUS Single Use System for Biopharma Process Market Outlook is the shift toward hybrid systems combining stainless steel and disposable components. Approximately 55% of manufacturers are adopting hybrid models to balance cost efficiency and performance. The use of advanced polymer materials has increased by 62%, enhancing durability and reducing risk of contamination. SUS Single Use System for Biopharma Process Market Research Report indicates that filtration and purification segments account for over 40% of SUS demand. Additionally, demand for single-use mixing systems has grown by 50%, driven by increased biologics production. Emerging markets in Asia-Pacific are witnessing over 45% growth in facility installations using SUS technologies.

SUS Single Use System for Biopharma Process Market Dynamics

DRIVER

"Rising demand for biologics and vaccines"

The SUS Single Use System for Biopharma Process Market is primarily driven by the increasing demand for biologics, vaccines, and biosimilars. Over 65% of pharmaceutical pipelines now focus on biologics, significantly boosting the need for flexible manufacturing systems. Single-use systems reduce cleaning time by 80% and operational downtime by 50%, enabling faster production cycles. More than 70% of vaccine manufacturing facilities utilize SUS to ensure contamination-free processing. The rapid expansion of cell and gene therapy production, with over 1,200 active clinical programs, further accelerates adoption. SUS Single Use System for Biopharma Process Market Opportunities continue to expand as companies prioritize efficiency and scalability.

RESTRAINTS

"Concerns over material compatibility and waste generation"

Despite strong growth, the SUS Single Use System for Biopharma Process Market faces challenges related to extractables, leachables, and environmental impact. Approximately 55% of manufacturers report concerns regarding material interactions affecting product quality. Disposal of plastic components contributes to over 30% increase in bioprocessing waste. Additionally, scalability limitations impact 48% of large-scale production facilities. Supply chain disruptions have affected 46% of SUS component availability, leading to delays in production. Regulatory scrutiny over material safety has increased by 40%, requiring extensive validation processes. These factors collectively restrain widespread adoption in certain large-scale applications.

OPPORTUNITY

"Expansion in personalized medicine and emerging markets"

The SUS Single Use System for Biopharma Process Market Forecast highlights significant opportunities in personalized medicine and emerging economies. Over 60% of new therapies focus on personalized treatments, requiring flexible and small-batch manufacturing systems. Asia-Pacific accounts for over 45% of new facility investments, driven by increasing healthcare infrastructure. The adoption of SUS in contract manufacturing organizations has grown by 68%, enabling faster market entry for new therapies. Technological advancements in polymer science have improved system reliability by 50%. SUS Single Use System for Biopharma Process Market Insights indicate that decentralized manufacturing models are gaining traction, creating new growth avenues.

CHALLENGE

"High dependency on supply chain and standardization issues"

The SUS Single Use System for Biopharma Process Market faces challenges related to supply chain dependency and lack of standardization. Over 50% of manufacturers rely on a limited number of suppliers for critical components, increasing vulnerability to disruptions. Standardization issues affect 45% of integration processes, leading to compatibility challenges between systems. The absence of universal guidelines impacts 40% of adoption decisions among large pharmaceutical companies. Additionally, training requirements for SUS handling have increased by 35%, adding operational complexity. SUS Single Use System for Biopharma Process Market Analysis suggests that addressing these challenges is crucial for long-term scalability and efficiency.

SUS Single Use System for Biopharma Process Market Segmentation

The SUS Single Use System for Biopharma Process Market segmentation highlights strong diversification across type and application, with over 60% adoption in upstream processing and 40% in downstream workflows. By type, single-use bioreactors account for more than 35% utilization, followed by disposable filtration systems at 30%, sterile bags at 25%, and other systems at 10%. By application, bio-pharmacy contributes nearly 70% of usage, while CDMO services represent 30%, reflecting the increasing outsourcing trend in biopharma manufacturing processes globally.

Download Free Sample to learn more about this report.

BY TYPE

Single-use Bioreactor: Single-use bioreactors represent a dominant segment in the SUS Single Use System for Biopharma Process Market, accounting for over 35% of total system utilization across global biopharmaceutical manufacturing facilities. These systems are extensively deployed in upstream processing, where more than 65% of biologics production relies on disposable bioreactors due to their ability to eliminate cleaning validation and reduce cross-contamination risks by over 80%. The global installed base of single-use bioreactors exceeds 20,000 units, with capacities ranging from 50 liters to over 2,000 liters, supporting both clinical and commercial scale production. Approximately 70% of monoclonal antibody production processes use single-use bioreactors, while their application in cell and gene therapy manufacturing has increased by over 60%. 

Disposable Sterile Bags: Disposable sterile bags account for approximately 25% of the SUS Single Use System for Biopharma Process Market, playing a critical role in storage, transport, and mixing of biopharmaceutical fluids. Over 80% of fluid handling processes in biopharma facilities utilize sterile bags, with capacities ranging from 1 liter to over 3,000 liters. These bags are essential in maintaining sterility and reducing contamination risks by up to 90%. More than 65% of downstream processing operations rely on sterile bags for buffer preparation and storage. Their flexibility and ease of integration into existing systems have led to a 60% increase in adoption across contract manufacturing organizations. Additionally, the use of multi-layer polymer films has enhanced durability and reduced leakage incidents by 40%. 

Disposable Filtration System: Disposable filtration systems represent nearly 30% of the SUS Single Use System for Biopharma Process Market, with widespread use in both upstream and downstream processing. Over 75% of purification processes incorporate single-use filtration systems to ensure product quality and sterility. These systems are capable of removing contaminants with efficiency rates exceeding 99%, making them essential for biologics production. Approximately 70% of vaccine manufacturing processes rely on disposable filtration technologies. The use of these systems reduces process downtime by 45% and increases filtration efficiency by 50% compared to traditional stainless-steel systems. Adoption has grown significantly in continuous bioprocessing environments, where over 60% of facilities use disposable filtration solutions. 

Other: The “Other” category in the SUS Single Use System for Biopharma Process Market includes components such as single-use mixers, connectors, sensors, and tubing assemblies, collectively accounting for around 10% of market usage. These components are critical in ensuring seamless integration of single-use systems across bioprocessing workflows. Over 65% of biopharma facilities utilize disposable mixers for buffer preparation, with mixing efficiency improved by 50% compared to traditional systems. Single-use connectors and tubing systems are used in more than 70% of fluid transfer processes, reducing contamination risks by 85%. The adoption of disposable sensors has increased by 45%, enabling real-time monitoring of parameters such as pH and dissolved oxygen. 

BY APPLICATION

Bio-pharmacy: The bio-pharmacy segment dominates the SUS Single Use System for Biopharma Process Market, accounting for nearly 70% of total application usage. Over 75% of biologics manufacturing processes rely on single-use systems to improve efficiency and maintain sterility. Monoclonal antibody production, which represents more than 60% of biologics output, heavily depends on SUS technologies for both upstream and downstream processes. Additionally, over 65% of vaccine production facilities utilize single-use systems to meet high demand and ensure rapid scalability. The integration of SUS in bio-pharmacy reduces contamination risks by over 80% and decreases cleaning requirements entirely, leading to a 50% reduction in operational downtime. More than 1,200 biologics development programs globally use SUS components during clinical and commercial production stages. 

CDMO: Contract Development and Manufacturing Organizations (CDMO) represent approximately 30% of the SUS Single Use System for Biopharma Process Market application segment, driven by the increasing trend of outsourcing biopharmaceutical production. Over 68% of CDMOs utilize single-use systems to provide flexible and scalable manufacturing services to clients. These organizations handle more than 50% of biologics production outsourcing globally, with SUS technologies enabling rapid setup and reduced turnaround times by nearly 45%. Approximately 70% of CDMO facilities incorporate disposable bioreactors and filtration systems to accommodate multi-product manufacturing requirements. The use of SUS allows CDMOs to reduce capital investment by 40% and operational costs by 35%, making them highly competitive. 

SUS Single Use System for Biopharma Process Market Regional Outlook

The SUS Single Use System for Biopharma Process Market Outlook demonstrates strong regional diversification, with North America holding approximately 38% market share, Europe accounting for 30%, Asia-Pacific contributing 25%, and Middle East & Africa representing 7%. North America leads due to advanced biopharmaceutical infrastructure and high adoption rates exceeding 70% across manufacturing facilities. Europe follows with over 65% integration in biologics production. Asia-Pacific is witnessing rapid expansion with over 45% increase in facility installations. Middle East & Africa show emerging growth supported by improving healthcare infrastructure and increasing biologics demand across key regions.

Download Free Sample to learn more about this report.

NORTH AMERICA

North America dominates the SUS Single Use System for Biopharma Process Market with approximately 38% market share, supported by a highly developed biopharmaceutical industry and strong adoption of advanced manufacturing technologies. Over 75% of biopharma facilities in the region utilize single-use systems across upstream and downstream processes. The region hosts more than 1,000 biologics manufacturing facilities, with over 70% integrating disposable technologies for improved efficiency and contamination control. The adoption of single-use bioreactors exceeds 65%, while filtration systems are used in more than 60% of purification processes. The presence of over 1,500 ongoing biologics and biosimilar development programs further drives demand for flexible manufacturing solutions. Additionally, contract manufacturing organizations in North America account for more than 50% of outsourcing activities, with over 68% utilizing SUS technologies. The region also leads in innovation, with over 60% of new product developments focused on advanced polymer materials and automation integration. Regulatory support and investment in modular facilities have increased by 55%, enabling rapid deployment of manufacturing units. Furthermore, over 70% of vaccine production facilities in the region rely on single-use systems, highlighting their critical role in ensuring scalability and sterility. 

EUROPE

Europe holds approximately 30% of the SUS Single Use System for Biopharma Process Market share, driven by strong regulatory frameworks and increasing investment in biologics manufacturing. Over 65% of biopharmaceutical facilities in Europe have adopted single-use systems to enhance operational efficiency and reduce contamination risks. The region has more than 800 biologics manufacturing sites, with over 60% utilizing disposable technologies in upstream processing. Single-use filtration systems are employed in more than 55% of purification processes, ensuring high product quality. The demand for SUS is further supported by over 900 active biologics development programs across Europe. Contract manufacturing organizations account for nearly 45% of production outsourcing, with over 60% integrating SUS technologies. Additionally, the adoption of modular facilities has increased by 50%, enabling faster production setup and scalability. Europe also leads in sustainability initiatives, with over 40% of manufacturers focusing on recyclable and eco-friendly materials in SUS components. 

GERMANY SUS Single Use System for Biopharma Process Market

Germany accounts for approximately 28% of the European SUS Single Use System for Biopharma Process Market, making it one of the leading countries in the region. Over 70% of biopharmaceutical facilities in Germany have adopted single-use systems for manufacturing processes. The country hosts more than 150 biologics production facilities, with over 65% utilizing disposable bioreactors and filtration systems. The adoption of SUS in vaccine production exceeds 60%, driven by increasing demand for rapid and scalable manufacturing solutions. Additionally, Germany has over 200 active biologics development programs, contributing to the growing need for flexible production systems. The use of single-use technologies has reduced operational downtime by 50% and improved production efficiency by 55%. Contract manufacturing organizations in Germany account for nearly 40% of outsourcing activities, with over 60% integrating SUS technologies. The country also leads in technological innovation, with over 45% of manufacturers investing in advanced polymer materials and automation systems. Furthermore, the adoption of modular facilities has increased by 50%, enabling faster deployment of manufacturing units. 

UNITED KINGDOM SUS Single Use System for Biopharma Process Market

The United Kingdom contributes approximately 22% to the European SUS Single Use System for Biopharma Process Market, supported by a robust biopharmaceutical sector and increasing adoption of innovative manufacturing technologies. Over 65% of biopharma facilities in the UK utilize single-use systems for both upstream and downstream processes. The country has more than 120 biologics manufacturing sites, with over 60% integrating disposable technologies. The adoption of SUS in vaccine production exceeds 55%, reflecting the growing demand for scalable manufacturing solutions. Additionally, the UK hosts over 180 biologics development programs, driving the need for flexible production systems. Contract manufacturing organizations account for nearly 35% of outsourcing activities, with over 58% utilizing SUS technologies. The use of single-use systems has reduced contamination risks by over 80% and improved operational efficiency by 50%. The UK also focuses on sustainability, with over 40% of manufacturers adopting eco-friendly materials in SUS components. Furthermore, the adoption of automation in single-use systems has increased by 55%, enhancing process consistency and reducing human intervention.

ASIA-PACIFIC

Asia-Pacific accounts for approximately 25% of the SUS Single Use System for Biopharma Process Market and is the fastest-growing region in terms of facility expansion and technology adoption. Over 45% of new biopharmaceutical manufacturing facilities in the region incorporate single-use systems, reflecting increasing demand for cost-effective and flexible production solutions. The region hosts more than 700 biologics manufacturing sites, with over 55% utilizing disposable technologies. The adoption of single-use bioreactors exceeds 50%, while filtration systems are used in more than 45% of purification processes. Additionally, over 800 biologics development programs are active in Asia-Pacific, driving demand for SUS technologies. Contract manufacturing organizations account for nearly 40% of outsourcing activities, with over 60% integrating single-use systems. The region also benefits from lower operational costs, with SUS adoption reducing capital investment by 40% and operational costs by 35%. Government support and investment in healthcare infrastructure have increased by 50%, further boosting market growth. The demand for vaccines and biosimilars, which accounts for over 60% of production in the region, continues to drive adoption of single-use systems.

JAPAN SUS Single Use System for Biopharma Process Market

Japan represents approximately 18% of the Asia-Pacific SUS Single Use System for Biopharma Process Market, driven by advanced healthcare infrastructure and strong focus on innovation. Over 60% of biopharma facilities in Japan utilize single-use systems for manufacturing processes. The country has more than 100 biologics production facilities, with over 55% integrating disposable technologies. The adoption of SUS in vaccine production exceeds 50%, supported by increasing demand for rapid and scalable manufacturing. Additionally, Japan hosts over 150 biologics development programs, contributing to the growing need for flexible production systems. The use of single-use technologies has reduced operational downtime by 45% and improved production efficiency by 50%. Contract manufacturing organizations account for nearly 30% of outsourcing activities, with over 55% utilizing SUS technologies. Japan also focuses on technological advancements, with over 40% of manufacturers investing in automation and advanced materials.

CHINA SUS Single Use System for Biopharma Process Market

China accounts for approximately 35% of the Asia-Pacific SUS Single Use System for Biopharma Process Market, making it a key contributor to regional growth. Over 55% of biopharmaceutical facilities in China have adopted single-use systems for manufacturing processes. The country hosts more than 300 biologics production facilities, with over 50% utilizing disposable technologies. The adoption of SUS in vaccine production exceeds 60%, driven by increasing demand for large-scale manufacturing. Additionally, China has over 400 active biologics development programs, contributing to the growing need for flexible production systems. Contract manufacturing organizations account for nearly 45% of outsourcing activities, with over 60% integrating SUS technologies. The use of single-use systems has reduced operational costs by 35% and improved production efficiency by 50%. Government support and investment in healthcare infrastructure have increased by 55%, further boosting adoption of SUS technologies.

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for approximately 7% of the SUS Single Use System for Biopharma Process Market, with growing adoption driven by improving healthcare infrastructure and increasing demand for biologics. Over 40% of biopharmaceutical facilities in the region have integrated single-use systems into their manufacturing processes. The region hosts more than 150 biologics production facilities, with over 45% utilizing disposable technologies. The adoption of single-use bioreactors exceeds 40%, while filtration systems are used in more than 35% of purification processes. Additionally, over 200 biologics development programs are active in the region, driving demand for SUS technologies. Contract manufacturing organizations account for nearly 30% of outsourcing activities, with over 50% utilizing single-use systems. Government investments in healthcare infrastructure have increased by 45%, supporting the expansion of biopharmaceutical manufacturing capabilities. The demand for vaccines, which accounts for over 50% of production in the region, continues to drive adoption of SUS technologies.

List of Key SUS Single Use System for Biopharma Process Market Companies

• SATAKE MultiMix
• Danaher
• Thermo Fisher
• Sartorius
• Merck
• Lepure China
• JYSS Bio-Engineering
• Tofflon
• Duoning Biotechnology
• ABEC
• AUSTAR

Top Two Companies with Highest Share

• Thermo Fisher: 22% share supported by over 70% adoption in integrated bioprocessing solutions and 65% utilization across global biologics manufacturing facilities.
• Sartorius: 18% share driven by 60% penetration in single-use bioreactors and 58% adoption in upstream and downstream processing systems.

Investment Analysis and Opportunities

The SUS Single Use System for Biopharma Process Market is witnessing strong investment activity driven by increasing demand for biologics and flexible manufacturing systems. Over 65% of biopharmaceutical companies are investing in single-use technologies to enhance production efficiency and reduce contamination risks. Approximately 60% of new manufacturing facilities are designed with modular setups incorporating SUS technologies. Investment in automation and digital integration has increased by 55%, improving operational efficiency and reducing human intervention. Additionally, over 50% of investments are directed toward advanced polymer materials to improve durability and performance of single-use components. Contract manufacturing organizations are allocating nearly 45% of their capital expenditure toward SUS adoption to meet growing outsourcing demand.

Significant opportunities exist in emerging markets, where over 48% of new biopharma facilities are adopting single-use systems to reduce infrastructure costs and accelerate production timelines. Asia-Pacific alone accounts for more than 45% of new investments in SUS-based facilities. The rise in personalized medicine, representing over 60% of new therapeutic developments, is further driving investment in flexible manufacturing solutions. Partnerships and collaborations have increased by 52%, enabling technology transfer and expansion of SUS capabilities. Additionally, over 58% of companies are focusing on sustainability initiatives, including recyclable materials and waste reduction strategies. These investment trends highlight strong growth potential and expanding opportunities across the SUS Single Use System for Biopharma Process Market.

New Products Development

New product development in the SUS Single Use System for Biopharma Process Market is focused on enhancing efficiency, scalability, and safety. Over 62% of manufacturers are developing advanced single-use bioreactors with improved sensor integration and automation capabilities. The introduction of high-capacity disposable bioreactors has increased production efficiency by 50% and reduced setup time by 45%. Additionally, more than 58% of companies are innovating in filtration technologies, with new membrane systems achieving over 99% impurity removal efficiency. The development of multi-layer polymer materials has improved durability by 40% and reduced leakage risks significantly.

The market is also witnessing advancements in integrated single-use systems, with over 55% of new products designed for end-to-end bioprocessing applications. Disposable mixing systems have improved blending efficiency by 48%, while single-use sensors have enhanced real-time monitoring accuracy by 52%. More than 60% of new product launches focus on compatibility with automation platforms, enabling seamless integration into digital manufacturing environments. Additionally, over 50% of innovations target sustainability, including biodegradable materials and reduced plastic usage. These developments are transforming the SUS Single Use System for Biopharma Process Market by improving operational efficiency and supporting next-generation biopharmaceutical production.

Five Recent Developments

• Thermo Fisher: Expanded its single-use bioreactor portfolio with advanced automation features, increasing process efficiency by 55% and reducing manual intervention by 50%, while improving scalability across biologics manufacturing facilities.
• Sartorius: Introduced next-generation filtration systems with enhanced membrane technology, achieving over 99% impurity removal and increasing throughput capacity by 60% in downstream processing applications.
• Merck: Developed innovative single-use mixing systems that improved blending efficiency by 48% and reduced processing time by 45%, supporting large-scale vaccine production and biologics manufacturing.
• Danaher: Enhanced its disposable bioprocessing solutions with integrated digital monitoring systems, increasing data accuracy by 52% and enabling real-time process optimization across manufacturing workflows.
• ABEC: Launched high-capacity single-use bioreactors designed for cell and gene therapy production, improving production flexibility by 50% and reducing contamination risks by over 80%.

Report Coverage Of SUS Single Use System for Biopharma Process Market

The SUS Single Use System for Biopharma Process Market Report provides comprehensive insights into market dynamics, segmentation, competitive landscape, and regional performance. The report covers over 90% of the global market, analyzing key segments such as single-use bioreactors, filtration systems, and sterile bags. It highlights that more than 70% of biopharma facilities have adopted single-use technologies, with upstream processing accounting for over 60% of utilization. The report also examines application areas, including bio-pharmacy and CDMO, which collectively contribute nearly 100% of market demand. Additionally, it evaluates key market drivers, restraints, opportunities, and challenges using percentage-based data and industry-specific insights.

The report further includes detailed analysis of regional markets, with North America holding approximately 38% share, Europe 30%, Asia-Pacific 25%, and Middle East & Africa 7%. It provides insights into technological advancements, with over 60% of innovations focused on automation and advanced materials. The competitive landscape section covers more than 80% of key market players, analyzing their strategies, product portfolios, and recent developments. Furthermore, the report identifies investment trends, with over 65% of companies increasing spending on single-use technologies. It also highlights emerging trends such as modular facilities and hybrid systems, which are adopted by over 55% of manufacturers globally.